Standiford T J, Kunkel S L, Phan S H, Rollins B J, Strieter R M
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0360.
J Biol Chem. 1991 May 25;266(15):9912-8.
Many acute and chronic lung diseases are characterized by the presence of increased numbers of activated macrophages. These macrophages are derived predominantly from newly recruited peripheral blood monocytes and may play a role in the amplification and perpetuation of an initial lung insult. The process of inflammatory cell recruitment is poorly understood, although the expression of inflammatory cell-specific chemoattractants and subsequent generation of chemotactic gradients is likely involved. Although immune cells such as macrophages and lymphocytes are known to generate several inflammatory cell chemoattractants, parenchymal cells can also synthesize and secrete a number of bioactive factors. We now demonstrate the generation of significant monocyte chemotactic activity from tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta-treated pulmonary type II-like epithelial cells (A549). The predominant inducible monocyte chemotaxin had an estimated molecular mass of approximately 14-15 kDa and was neutralized by specific antibody to human monocyte chemotactic protein-1 (MCP-1). Induction of activity was accompanied by increases in steady-state mRNA level for MCP-1. These data are consistent with the induction of MCP-1 expression from A549 cells by TNF and IL-1. MCP-1 production from A549 cells could be induced by lipopolysaccharide (LPS)-stimulated alveolar macrophage (AM)-conditioned media, but not by LPS alone. The inducing activity in AM-conditioned media was neutralized with specific antibodies to IL-1 beta, but not TNF-alpha. Our findings suggest that the alveolar epithelium can participate in inflammatory cell recruitment via the production of MCP-1 and that cytokine networking between contiguous alveolar macrophages and the pulmonary epithelium may be essential for parenchymal cell MCP-1 expression.
许多急性和慢性肺部疾病的特征是活化巨噬细胞数量增加。这些巨噬细胞主要来源于新招募的外周血单核细胞,可能在初始肺部损伤的放大和持续过程中发挥作用。尽管炎症细胞特异性趋化因子的表达以及随后趋化梯度的产生可能参与其中,但炎症细胞募集的过程仍知之甚少。虽然已知巨噬细胞和淋巴细胞等免疫细胞会产生多种炎症细胞趋化因子,但实质细胞也能合成和分泌一些生物活性因子。我们现在证明,经肿瘤坏死因子(TNF)-α和白细胞介素(IL)-1β处理的肺II型样上皮细胞(A549)可产生显著的单核细胞趋化活性。主要的诱导性单核细胞趋化蛋白估计分子量约为14 - 15 kDa,并被抗人单核细胞趋化蛋白-1(MCP-1)的特异性抗体中和。活性的诱导伴随着MCP-1稳态mRNA水平的增加。这些数据与TNF和IL-1诱导A549细胞表达MCP-1一致。脂多糖(LPS)刺激的肺泡巨噬细胞(AM)条件培养基可诱导A549细胞产生MCP-1,但单独的LPS则不能。AM条件培养基中的诱导活性可被抗IL-1β的特异性抗体中和,但不能被抗TNF-α的抗体中和。我们的研究结果表明,肺泡上皮可通过产生MCP-1参与炎症细胞募集,相邻肺泡巨噬细胞与肺上皮之间的细胞因子网络可能对实质细胞MCP-1的表达至关重要。